**Ketogenic Diets as an Adjuvant Therapy in Glioblastoma (The KEATING Trial): Study Protocol for a Randomised Pilot Study**

**Authors**

Kirsty J Martin-McGill, Institute of Translational Medicine, University of Liverpool and The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK. L9 7LJ. Kirsty.martin@liverpool.ac.uk (corresponding author).

Prof Anthony G Marson, Institute of Translational Medicine, University of Liverpool and The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK. L9 7LJ. A.G.Marson@liverpool.ac.uk

Dr Catrin Tudur Smith, Department of Biostatistics, University of Liverpool, Brownlow Hill, Liverpool, UK. L69 3BX. Cat1@liverpool.ac.uk

Mr Michael D Jenkinson, Institute of Translational Medicine, University of Liverpool and The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK. L9 7LJ. Michael.jenkinson@liverpool.ac.uk

**Sponsor**

University of Liverpool

c/o Alex Astor, Research Support Office, 2nd Floor, D Block, Waterhouse Building, 3 Brownlow Street, Liverpool, L69 3GL. sponsor@liv.ac.uk

**Version 1, 13 DEC 2016.**

**Abstract**

Background: Glioblastoma is the commonest form of malignant brain tumour in adults, affecting 2-3 people per 100,000 per year. Despite current treatment options including surgical resection, radiotherapy and temozolomide chemotherapy, overall survival at two years is approximately 27%, with a median survival of 12-14 months. The ketogenic diet (KD) is postulated to work by simulating the metabolic response to fasting by promoting the utilisation of ketones as a primary energy source, and depriving the glycolytic pathways utilised by malignant glioma cells for growth. At present there is no consensus as to which KD is preferable, with previous case series using different KDs, at different points in the treatment pathway. The aim of this randomised pilot study is to investigate protocol feasibility, tolerability and the impact on patient health and quality of life of two different KDs within an NHS setting. The results of this pilot study will inform which KD will be most deliverable and adhered to by patients in order to test for effectiveness in future trials.

Methods: A prospective, non-blinded, randomised, pilot study will be undertaken in 12 patients with newly diagnosed glioblastoma treated by surgical resection. Patients will be randomised in a ratio of 1:1, using a permuted block randomisation method to one of two diets; the modified ketogenic diet and the medium chain triglyceride ketogenic diet. Primary data collection will take place twelve weeks after starting the diet and secondary data collection after twelve months. Feasibility will be assessed by retention and recruitment rates, ability to enrol patients prior to starting chemoradiotherapy, dietary compliance and adjustments, ketone levels, glucose levels and intervention time. Patient impact will be assessed through quality of life and food acceptability questionnaires, gastrointestinal side effects and changes to biochemical markers and anthropometric measures, assessed at regular intervals.

Discussion: The results of this pilot study will be used to inform the feasibility, methodological design and power calculations of future phase III clinical trials investigating the effectiveness of KD as an adjuvant therapy in the management of glioblastoma.

Trial registration: ISRCTN71665562 and NCT03075514.

**Keywords**

Ketogenic diet, Modified ketogenic diet, Medium chain triglyceride diet, Glioblastoma.

**Background**

Glioblastoma (GB) is the commonest form of malignant brain tumour in adults, affecting 2-3 people per 100,000 per year (1). Despite current treatment options including maximal safe resection, radiotherapy and temozolomide chemotherapy (2), overall survival at two years remains poor (median survival of 12-14 months (3)). Several recent trials investigating newer chemotherapy agents (e.g. RTOG 0825 - Bevacizumab trial (4)) and targeted therapies (e.g. CENTRIC – Celengitide trial (5)) have not resulted in any improvement to prognosis. Therefore, alternative treatment options are being explored and there is increasing clinical interest for investigating the ketogenic diet (KD) therapy as an adjuvant treatment for patients with GB.

KDs are high fat, low carbohydrate diets, resulting in the production of ketones as a primary energy source, depriving the glycolytic pathways utilised for growth by GBs. Laboratory studies of the effect of KDs in glioma mouse models have demonstrated increased survival (6), enhanced radiotherapy sensitivity (7), improved chemotherapy signalling (8) and reduced peritumoural oedema (9).

Recent studies investigating the use of the KD in humans have focused on the feasibility, safety and efficacy, in view of the fact that the diet may be considered unpalatable and unacceptable to patients with a limited life expectancy. Several small case studies (10–13) and one pilot study (14) have been reported.

Various forms of the KD have been developed over recent years to improve palatability and compliance, whilst maintaining efficacy within the diets primary evidence base of paediatric epilepsy (15,16). The two least restrictive KD are the modified ketogenic diet (MKD) and the medium chain triglyceride (MCT) KD, both of which are currently used for treating paediatric epilepsy within the National Health Service (NHS) and have been utilised in previous glioblastoma case series.

The MKD induces ketosis through encouraging a high fat and low carbohydrate intake, without limiting protein, fluid or energy intakes. There is no need for a fasting start or hospitalisation to commence the diet (17). MKD is likely to be the most flexible and palatable KDs; therefore may be more suitable for adults undergoing oncological treatments.

MCT KD was first described by Huttenlocher, Wilbourn and Signore (1971) as a modification to the classic KD. It allows for the inclusion of larger portions of carbohydrate, thus, improving dietary tolerance and acceptability (18). A recent study by Martuscello et al., (2015) investigating the use of MCT KD in GB animal models found slower tumour progression, increased survival, increased body weight and positive changes to serum lipids, in comparison to a standard KD and controls (19).

**Rationale**

The effect of lifestyle factors (including diet) on tumours is one of the top ten priority areas for research identified by the James Lind Priority Setting Partnership in the Neuro-Oncology community (20). To enable an adequately powered randomised controlled trial to be undertaken, investigating the efficacy of the ketogenic diet in the therapeutic management of glioblastoma, this preliminary study is important to test protocol methodology and explore potential impact on patient quality of life and health. At present it is not known which KD, if any, holds promise for further investigation of effectiveness. Therefore, this study will directly compare two KD (MKD and MCT KD) to determine which diet is most deliverable and best adhered to by patients in order to test clinical effectiveness, as a primary outcome (overall survival) in a future definitive trial, within an NHS glioblastoma population. In a trial of effectiveness, a control group would be required (such as ‘healthy eating’) and directly compared to the ‘successful’ dietary arm from this pilot.

**Methods**

*Aims and objectives*

The aim of this trial is to investigate protocol feasibility and patient impact by comparing two KDs in an NHS setting, with a view to informing the design of future phase III clinical trials. The primary objective is to estimate retention rates to inform sample size calculations of future, definitive trials. Secondary objectives in relation to protocol feasibility include estimations of recruitment, enrolment and long term retention rates and to obtain data on dietary compliance, dietary adjustments required to achieve ketosis, ketone and glucose levels, intervention time, protocol refinements and completeness of data. Secondary objectives related to patient impact include collating data on quality of life, food acceptability, gastrointestinal side effects, biochemical markers and anthropometry.

*Design*

This is a prospective, non-blinded, randomised, pilot study which will be undertaken in patients diagnosed with newly diagnosed GB. Patients will be randomised to receive one of two types of KD; MKD or MCT KD. The trial has received ethical approval from the North West - Greater Manchester West Research Ethics Committee (17/NW/0013) and has been registered with the International Standard Randomised Controlled Trial Number registry (reference number 71665562) and ClinicalTrials.Gov (reference number NCT03075514).

*Setting*

This single centre pilot trial will be conducted at The Walton Centre NHS Foundation Trust (WCFT), Liverpool, UK. WCFT is a dedicated neuroscience hospital.

*Participants*

The target population is adults with newly, histologically diagnosed GB. All patients considered for the trial must meet the following inclusion criteria:

1. Age ≥16 years,
2. Patient at WCFT,
3. Performance status ≤2[[1]](#footnote-1) (numerical grading of patients well-being and function) (21),
4. Confirmed histological diagnosis of GB (WHO grade IV, (22)),
5. Undergone surgical resection and will go onto receive chemoradiotherapy with temozolomide.

Patients exhibiting the following will be excluded from the study:

1. Having any prior use of a KD,
2. Kidney dysfunction,
3. Liver dysfunction,
4. Gall bladder dysfunction,
5. Metabolic disorder,
6. Eating disorder (history of anorexia nervosa, bulimia nervosa, binge eating disorder),
7. Diabetes (requiring medication),
8. Body mass index (BMI) ≤18.5kg/m2 ,
9. Use of weight loss medications,
10. Currently pregnant,
11. Performance status ≥3 (21).

*Sample size and recruitment*

This study is being conducted as part of a PhD thesis. Twelve patients will be recruited over a twelve months period. Previous feasibility work shows this recruitment rate is achievable. Patients will be identified at a weekly neuro-oncology multi-disciplinary team (MDT) meeting; with documentation within MDT case sheet deemed an appropriate referral. Patients will be approached for recruitment after surgery and histological diagnosis of GB. Recruitment will take place for twelve months from the date of opening. Patients referred for the KEATING trial will be offered a screening appointment. A screening log will be maintained for all patients referred to the trial and reasons for ineligibility will be noted.

*Allocation strategy*

Patients will be randomised into MKD or MCT KD groups. The patients will be informed of diet group by telephone. A permuted block randomisation method will be adopted, at a 1:1 ratio using 'sealedenvelope'™ randomisation system. This will be set up and administered by the statistician (CTS), who is not involved with the recruiting of patients.

*Intervention design*

All participants will be invited to attend clinical consultations pre diet, on initiating diet, six weeks from initiation, twelve weeks from initiation (primary completion) and every three months for a total of twelve months (secondary completion) or until dietary discontinuation if prior to this. Telephone consultations will take place post initiation at weeks one, three and nine to enable dietary ‘fine tuning’ (figures 1 & 2). All consultations will be undertaken with the same research dietitian. It is not possible to blind the participants or the investigators due to differences between the diets and dietary education required.

*Dietary intervention*

Dietary intervention following surgery and prior to starting chemoradiotherapy. Oncology treatment will continue in line with the standard of care.

Both MKD and MCT KD are high in fat and low in carbohydrate. However, they contain different amounts and types of fat. The MKD provides fat to 80% of total energy requirements (predominately long chain fatty acids) and 5% carbohydrate. Whilst the MCT KD provides fat to 75% of total energy requirements (30% of which is medium chain fatty acids, consumed via a nutritional supplement), and 10% carbohydrate. Protein is allowed freely in both diets.

Patients (and relatives when appropriate) will receive dietetic counselling and be provided with dietary literature to calculate intakes of these food groups. All patients will commence the diet at home, without a fasting start.

Energy requirements will be appropriate for patient’s age, weight, activity and metabolic stress, monitored through weight checks. To estimate energy requirements a three day weighed food diary will be analysed using DietPlan 7© (Forestfield Software LTD, Horsham, UK) and compared to the Parenteral and Enteral Nutrition Group (PENG) energy requirements (23–29) , from which a mean energy requirement will be estimated. The requirements can be tailored for weight loss, gain or maintenance dependent upon the patient’s needs and wishes. Dietary requirements will be recalculated each time a new weight is obtained.

Seven day diet plans will be calculated by the dietitian based upon total energy requirements. Nutritional content will be analysed using DietPlan 7© (Forestfield Software LTD, Horsham, UK) to ensure appropriate proportions of carbohydrate, fat and protein.

*Associated medications and treatments*

Medications permitted: all medications with the exception of those specified below.

Medications not permitted: weight loss medications (including [Orlistat](http://www.webmd.com/drugs/2/drug-17220/orlistat%2Boral/details), [Belviq](http://www.webmd.com/drugs/2/drug-164439/belviq%2Boral/details), Contrave, Saxenda, [Phentermine](http://www.webmd.com/drugs/2/drug-4151/phentermine%2Boral/details) and [Qsymia](http://www.webmd.com/drugs/2/drug-162311/qsymia%2Boral/details)) and any agents used in diabetic therapy (including Biguanides, Sulfonylureas, Meglitinide derivatives, Alpha-glucosidase inhibitors, Thiazolidinediones (TZDs), Glucagonlike peptide–1 (GLP-1) agonists, Dipeptidyl peptidase IV (DPP-4) Inhibitors, Selective sodium-glucose transporter-2 (SGLT-2) inhibitors, Insulins, Amylinomimetics, Bile acid sequestrants and Dopamine agonists).

Data will be collected on use of corticosteroids, antiemetics, laxatives and antiepileptic drugs. Data will also be collected for nutritional supplements consumed by the patient.

*Baseline data collection*

Baseline data will be collected at the initial consultation once eligibility is confirmed and written consent obtained by the investigator (appendix 1). Baseline data will include past medical history, symptoms at presentation, tumour location, surgical procedure, histopathology and molecular pathology subtypes for glioblastoma (MGMT, IDH-1, ATRX, 1p/19q status), current medication (prescribed and purchased), current nutritional supplementation (vitamins, minerals, herbal and nutritional products), food allergies or intolerances, level of physical activity (as defined by DH, 1991), food or fluid texture modification, use of enteral feeding tube, anthropometry (height, weight, BMI, mid arm muscle circumference, triceps skin fold, mid arm muscle circumference, hand grip strength, waist circumference and fat mass), biochemistry (fasting lipid, fasting glucose, liver, renal and bone profiles), habitual 3 day weighed food diary, habitual gastrointestinal complaints, quality of life measures (EORTC QLQ C30 and QLQ BN 20 questionnaires) and habitual food acceptability (Food Acceptability Questionnaire, (30)).

Histopathology and molecular pathology subtypes for glioblastoma (MGMT, IDH-1, ATRX, 1p/19q status) classification will be conducted as per the current standard of care.

MRI will be conducted as per the current standard of care for patients with GB (31), resulting in scans at the following intervals:

* Pre surgery
* Post-surgery (within 72 hours)
* Pre radiotherapy
* 1 month post radiotherapy
* Mid chemotherapy (after 3 cycles)
* Post chemotherapy (after 6 cycles)
* Every 6 months from 12-24 months

MRI scans will include T1 ± gadolinium, T2 and fluid-attenuated inversion recovery (FLAIR) sequences. Extent of resection on post-operative MRI will be determined and recurrence will be measured according to the Response Assessment in Neuro-Oncology (RANO) criteria (32).

Changes to medications and treatment will be recorded; these are permitted to be altered in-line with the treating oncologist/neurosurgeons recommendations. Details of concomitant radiotherapy and chemotherapy and adjuvant chemotherapy will be noted in the CRF.

*Primary outcome measures*

1. Assess retention and drop-out rates, defined as:
	1. The number of patients who start randomised treatment as a proportion of the number randomised, with reasons for non-compliance.
	2. The number of patients who complete twelve weeks of diet as a proportion of the number randomised, with reasons for non-compliance.
	3. The time to dietary discontinuation (week twelve or duration to discontinuation if prior to this).
	4. A description of barriers and facilitators to data collection and participant retention will also be included.

*Secondary outcome measures*

1. Estimation of recruitment rates
	1. Actual recruitment rates will be compared to proposed recruitment figures (twelve patients over twelve months) with purpose of demonstrating trial feasibility for future, potential phase III clinical trials.
2. Enrolment of patients
	1. Ability to comply with protocol enrolment time lines will be assessed by the number of patients initiated on diet prior to starting chemoradiation treatment. This will inform the feasible time lines in future clinical trials.
3. Long term retention
	1. The time to dietary discontinuation after week twelve.
4. Dietary adjustments required to achieve ketosis
	1. Dietary adjustments advised by the dietitian will be recorded in the case report form (CRF), to inform the macronutrient composition of MKD and MCT KD required to achieve ketosis in this population to inform future protocols.
5. Dietary compliance
	1. Dietary compliance will be self-reported by the patient at clinic appointments. The dietitian will also analyse self-reported three day weighed food diaries (completed at weeks six, twelve and every three months thereafter) using DietPlan 7© (nutritional analysis computer programme). The results will be compared to dietary fat and carbohydrate requirements (calculated at previous clinic appointment) and percentage compliance rates will be calculated.
6. MCT compliance
	1. MCT supplement compliance will be self-reported through three day weighed food diaries collected at week six, week twelve and every three months thereafter. The results will be compared to the MCT dose advised (at previous clinic appointment) and a percentage compliance rate will be calculated.
7. Ketone and glucose levels
	1. Ketosis will be monitored by patients self-reporting urinary ketones levels twice per day for the first six weeks then then once per week thereafter. Adequate urinary ketosis is defined as ≥4mmol/L.
	2. Blood ketones and blood glucose levels will be monitored weekly. Adequate blood glucose levels are defined as 3-5mmol/L.
	3. There are no robust guidelines for adequate levels of blood ketosis in adults with GB, however from preliminary work by Meidenbauer et al. (2015), levels of 2-4mmol/L to be beneficial, therefore patients will be asked to record levels to aid future research (33).
	4. All figures will be recorded in the ketone/glucose diary provided. The dietitian will assess these at each point of contact.
8. Dietetic time required for the interventions
	1. Dietetic time spent on both clinical and non-clinical activities related to the trial will be recorded to aid future protocol design.
9. Protocol refinements required
	1. Deviations from the protocol will be documented on the deviation log. This will be used to refine future protocols and inform future clinical trials.
10. Sample size estimates for future trials
	1. Data synthesised from this pilot will inform sample size calculations for future phase III clinical trials, based on the primary outcome measure of retention.
11. Completeness of data for all trial outcomes
	1. Completeness of documented data will be assessed to inform feasibility of future clinical trials.
12. Quality of life
	1. Quality of life will be evaluated though the genertic EORTC QLQ C30 and brain cancer specific QLQ BN 20 validated questionnaires prior to commencing the diet, at week six, week twelve and every three months thereafter or at point of dietary discontinuation if prior to this.
13. Food acceptability
	1. Food acceptability will be assessed through the non-validated Food Acceptability Questionnaire (30) completed prior to commencing the diet, at week six, week twelve and every three months thereafter or at point of dietary discontinuation if prior to this.
14. Gastrointestinal side effects
	1. Gastrointestinal side effects will be quantified from the EORCT QLQ C30 questionnaire and through informal clinic assessments. The Common Terminology Criteria for Adverse Events ([CTCAE], version 4.0) will be used to grade gastrointestinal side effects.
15. Changes to biochemical markers
	1. Biochemical markers (fasting lipid, fasting glucose, liver, renal and bone profiles) will be undertaken at baseline and repeated three monthly until discontinuation of diet.
16. Anthropometric changes
	1. Anthropometry (height, weight, body mass index (BMI), waist circumference, mid upper arm circumference (MUAC), mid arm muscle circumference (MAMC), tricep skin fold (TSF), hand grip strength (HGS) and fat mass) will be measured at baseline, week six, week twelve and every three months thereafter. All measurements will be undertaken as per measurement methodology cited in Parenteral and Enteral Nutrition Group (PENG), pocket guide to clinical nutrition (29).

*Withdrawal*

If there is a change in the patient’s condition that in the clinician’s opinion justifies dietary discontinuation or if the patient withdraws consent, the patient will be withdrawn from dietary treatment. In this case, data up until the point of withdrawal will be used in analysis. Unless the patient specifically withdraws consent further data will be gathered for progression free survival and overall survival analysis.

Patients will be made aware at the point of consent that they can withdraw at any time. No reason will be required. Should a patient withdraw, data will be included in the analysis until the point of withdrawal, unless the patient states otherwise. If they wish for their data to be excluded entirely, a CRF for destruction of data will be completed.

*Defining success*

Pilot success will be graded using a traffic light system. The pilot will be deemed a success and progression to phase III trial will be considered appropriate if the following criteria are met:

Green (go):

* Recruitment rate of ≥75% of target (n=9) achieved within the twelve month recruitment period.
* ≥75% of patients commenced KD prior to chemoradiotherapy.
* Retention rate of ≥75% at three months.
* Diet acceptable to ≥75% of patients at three months.
* ≥75% of the proposed data collection completed for each end point.

Amber (review):

* Recruitment rate of ≥50% of target (n=6) achieved within the twelve month recruitment period.
* ≥50% of patients commenced KD prior to chemoradiotherapy.
* Retention rate of ≥50% at three months.
* Diet acceptable to ≥50% of patients at three months.
* ≥50% of the proposed data collection completed for each end point.

Red (stop):

* Recruitment rate <50% of target (n=5) achieved within the twelve month recruitment period.
* <50% of patients commenced KD prior to chemoradiotherapy.
* Retention rate of <50% at three months.
* Diet acceptable to <50% of patients at three months.
* <75% of the proposed data collection completed for each end point.

Retention rate, dietary acceptance and data collection will be assessed for each diet independently. Recruitment rate and dietary commencement will be assessed using data combined from both arms.

Any components of the pilot considered not feasible or unacceptable to patients will be evaluated prior to progression onto phase III clinical trial is considered. The Shanyinde, Pickering, & Weatherall (2011) method will be used to categorise and assess the extent of the issue (34) and the Bugge et al., (2013) method will be used to evidence the decision making process (35).

*Statistical considerations*

Sample size

Feasibility data demonstrates a likely retention rate of 70% participants at 12 weeks. With a sample size of 12 we will be able to estimate retention rates of 70% to within a 95% confidence interval of ±25.93% (36)(Hooper, no date).  Billingham et al. (2013) demonstrate a median sample size of 30 (range 8-114 participants) for UK pilot studies, whilst Hertzog (2008) reports on the statistical adequacy for sample sizes of 10-40, thus further justifying a sample size of 12 for the current trial (37,38).

Analysis plan

A detailed analysis plan will be developed prior to the final analysis. In brief, descriptive statistics will be used to summarise retention, recruitment rates, enrolment adherence, dietary adjustments, dietetic time, dietary compliance, MCT supplement compliance, ketosis, anthropometry changes, biochemistry changes, quality of life, food acceptability and gastrointestinal side effects. The Kaplan-Meier survival curve will be estimated for overall survival and progression free survival and displayed graphically with 95% confidence intervals

**Discussion**

*Practical considerations*

When designing the trial we considered a number of practical issues, to enable implementation within an NHS setting.

When deciding on which KDs to include within the trial, nutritional adequacy and previous evidence base were considered. There are various types of KDs, offering varying contents of fat and carbohydrate. From the literature the two KDs previous cited in oncology case series include the MKD and the MCT KD (13,14,39,40). Both diets allow for the sufficient provision of protein, essential for patients undergoing oncological treatments, in comparison to the classic ketogenic diet which would not meet adult protein requirements. Both MCT and MKD are currently used in NHS practice for patients with refractory epilepsy.

In this trial the KD will be offered alongside current standard of care. In order to allow for future meta-analysis of data, the diet will be commenced post-surgical resection, prior to chemoradiotherpy in keeping with US centres (41,42). This theory is supported by previous animal models which illustrate the KD to enhance the effects of chemoradiation (6–8).

Methods for assessing ketone and glucose levels were also considered. Blood ketone and glucose levels can provide a more accurate result, when compared to urinary ketones, due to the effects of urinary dilution. However, blood monitoring is more invasive for the patient and considerably more expensive when considering trial design and potential future NHS implementation. The minimum ketone monitoring requirements cited by the International League Against Epilepsy Task Force for Diet Therapy state urinary ketones to be a minimum standard (43). Therefore, in keeping with this we will conduct urinary ketone monitoring, with additional weekly blood ketone and glucose levels (home finger prick testing), with a view to informing future methodology.

In terms of recruitment, 12 patients is an achievable target and suitable for a pilot study, however, an element of statistical uncertainty will be present. Therefore we have opted for descriptive statistical methods and will apply caution when interpreting results for any future study design.

*Data collection and storage*

Data will be pseudo anonymised and transferred onto a password protected electronic spreadsheet (Microsoft Excel©) held on University of Liverpool Active DataStore.

Data will be held for 10 years to allow for future retrospective comparisons to larger scale studies. After the trial is complete, the essential trial paper documentation and CRFs will be archived by the University of Liverpool Records Management Department and held at University Records Centre. Electronic data will be archived by the investigator, in the University of Liverpool Data Catalogue, as per the University of Liverpool, Research Data Management Policy. Source documents are held within the medical notes, therefore are retained in the Health Records Library of WCFT, as per the WCFT Clinical Records Management Policy.

*Patient and public involvement*

A PPI event was undertaken, seeking the active involvement of patients and public in identifying research priorities and outcome measures for KD in GB. Following feedback from the event improvements were made to patient information leaflets, plain language summary, recruitment processes, clinical consultations, along with reducing patient costs to enhance trial participation.

*Adverse events*

The main health risks associated with the diet include gastrointestinal intolerance (such as diarrhoea, constipation, nausea, reflux, abdominal discomfort), altered or raised cholesterol , kidney stones and decreased bone density (44).

To monitor these health risks biochemistry will be monitored every three months (renal, bone, LFT, fasting cholesterol and glucose). Gastrointestinal side effects will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE, version 4, (45)) and dietary adjustments will be made to aid symptom relief when possible.

All adverse events (AE) will be reported. The National Institute of Health Research (NIHR) ‘decision tree for adverse event reporting’ (46) will be used to grade AE and serious adverse events (SAE) severity.

An AE or SAE will be reported by the investigator; however the chief investigator will be responsible for determining causality. The trial would close early should SAEs occur as a direct result of the trial intervention.

Trigger monitoring will be adopted which will be managed by the University of Liverpool (the Sponsor).

All SAE will be reported to the Trial Steering Committee within one week of the event.

**Conclusion**

This pilot study will be the first in the UK to investigate the feasibility and tolerability of KD in GB patients. By testing protocol feasibility we will determine which diet is most deliverable and adhered to by patients, and this will inform the methodology of future phase III clinical trials, from which effectiveness could be determined. We will also generate data on diet acceptability and the impact on patient quality of life and anthropometry.

**Trial status**

Current protocol version 1, 13 DEC 2016. Recruitment began 01 APR 2017. Recruitment expected to be completed by 31 MAR 2018.

**List of abbreviations**

|  |  |
| --- | --- |
| AE | Adverse Event |
| ATRX | Alpha-thalassemia/mental retardation syndrome x-linked mutation  |
| BMI | Body Mass Index |
| CI | Chief Investigator  |
| CRF | Case Report Form |
| EORTC  | European Organisation for Research and Treatment of Cancer |
| FLAIR | Fluid-Attenuated Inversion Recovery |
| GB | Glioblastoma  |
| IDH-1 | Isocitrate Dehydrogenase 1 |
| KD | Ketogenic Diet |
| MCT KD | Medium Chain Triglyceride Ketogenic Diet |
| MDT | Multi-Disciplinary Team |
| MGMT | O6-methylguanin-DNA-methyltransferase |
| MKD | Modified Ketogenic Diet |
| MRI | Magnetic Resonance Imaging  |
| NHS | National Health Service |
| PENG | Parenteral and Enteral Nutrition Group |
| PPI | Patient and Public Involvement  |
| QLQ | Quality of Life Questionnaire |
| RANO | Response Assessment in Neuro-Oncology  |
| SAE | Serious Adverse Event  |
| UK | United Kingdom  |
| WCFT | Walton Centre NHS Foundation Trust |

**Declaration**

*Ethics approval and consent to participate*

The trial has received ethical approval from the North West - Greater Manchester West Research Ethics Committee (reference number IRAS 218992) and has been registered with the International Standard Randomised Controlled Trial Number registry (reference number 71665562) and ClinicalTrials.Gov (reference number NCT03075514).

*Indemnity*

The University of Liverpool as sponsor holds insurance for injury caused by participation in a clinical trial. The WCFT is an NHS trust, thus has a duty of care to its patients and a legal liable for acts of negligence by their employees, which includes those patients participating in the trial.

*Confidentiality*

All data will be pseudo anonymised in order to maintain patient confidentiality. All paper and electronic documentation will be stored securely. The Data Protection Act, Caldicott Principles and Good Clinical Practice guidelines will be followed at all times.

*Access to data*

Only members of the trial team will have access to the trial data.

*Protocol amendments*

Protocol amendments will be communicated to all relevant parties in writing (Sponsor, REC, HRA, Trial registry, investigators, participants and journals).

*Dissemination*

The trial will be undertaken as part of a PhD programme at the University of Liverpool. Completion of a thesis is proposed for July 2019.

Results of the trial will be published as soon as possible, in an appropriate peer reviewed journal and presented at appropriate conferences. The financial sponsor Vitaflo International Ltd will be acknowledged, however they will have no part in conducting or analysing the trial.

A newsletter detailing the findings of the trial will be circulated to those patients who are alive at time of completion, if the patient previously consented to receiving such information.

*Consent for publication*

Not applicable.

*Availability of data and materials*

Not applicable as trial protocol.

*Completing interests*

MDJ, AGM, CTS and KJM receive funding from Vitaflo (International) Ltd for KJM PhD studies. Vitaflo are independent to the study design and scientific content of this pilot study.

*Funding*

Funding for the trial was received from Vitaflo (International) Ltd via a PhD Studentship for KJM. Vitaflo also supplied the nutritional product, however did not contribute to or influence this trial protocol or publication.

*Author’s contributions*

KJM wrote the manuscript. MDJ, AGM and CTS reviewed manuscript with suggestions. All authors read and approved the final manuscript.

*Acknowledgements*

The authors would like to thank the Research, Development and Innovation team of The Walton Centre NHS Foundation Trust for their support.

**References**

1. Radhakrishnan K, Mokri B, Parisi JE, O’Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of rochester, minnesota. Ann Neurol [Internet]. 1995 Jan [cited 2017 Feb 10];37(1):67–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7818260

2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med [Internet]. 2005;352(10):987–96. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa043330

3. Krex D, Klink B, Hartmann C, Von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(10):2596–606.

4. Gilbert MR, Dignam JJ, Armstrong TSTS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.

5. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100–8.

6. Woolf EC, Scheck AC. The ketogenic diet for the treatment of malignant glioma. J Lipid Res [Internet]. 2015 Jan [cited 2017 Jan 24];56(1):5–10. Available from: http://www.jlr.org/lookup/doi/10.1194/jlr.R046797

7. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The Ketogenic Diet Is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma. Canoll P, editor. PLoS One [Internet]. 2012 May 1 [cited 2016 Nov 15];7(5):e36197. Available from: http://dx.plos.org/10.1371/journal.pone.0036197

8. Allen BG, Bhatia SK, Buatti JM, Brandt KE, Lindholm KE, Button AM, et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013;19(14).

9. Jiang Y-S, Wang F-R. Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J Neurooncol [Internet]. 2013 Aug 24 [cited 2017 Feb 10];114(1):25–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23703297

10. Kalamian M, Zupec-Kania B, Favara BE, Liepa GU. Ketogenic diet as adjunctive therapy for brain tumors. First Int Symp Diet Treat Epilepsy other Neurol Disord Poster Present. 2008;1.

11. Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab [Internet]. 2015 Dec 25 [cited 2017 Jan 26];3(3):1–10. Available from: http://www.cancerandmetabolism.com/content/3/1/3

12. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond) [Internet]. 2010 [cited 2017 Jan 25];7(33):1–7. Available from: http://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-7-33

13. Nebeling LC, Miraldi F, Shurin S, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr [Internet]. 1995 Apr [cited 2016 Nov 15];14(2):202–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7790697

14. Rieger J, Bähr O, Maurer GGD, Hattingen E, Franz K, Brucker D, et al. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol [Internet]. 2014 Apr 11 [cited 2017 Jan 24];45(6):1843–52. Available from: http://www.spandidos-publications.com/10.3892/ijo.2014.2382

15. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia [Internet]. 2009 May [cited 2017 Feb 10];50(5):1109–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19054400

16. Kossoff EH, McGrogan JR, Bluml RM, Pillas DJ, Rubenstein JE, Vining EP. A Modified Atkins Diet Is Effective for the Treatment of Intractable Pediatric Epilepsy. Epilepsia [Internet]. 2006 Feb [cited 2017 Feb 10];47(2):421–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16499770

17. Bergqvist AGC, Schall JI, Gallagher PR, Cnaan A, Stallings VA. Fasting versus Gradual Initiation of the Ketogenic Diet: A Prospective, Randomized Clinical Trial of Efficacy. Epilepsia [Internet]. 2005 Nov [cited 2017 Feb 10];46(11):1810–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16302862

18. Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology [Internet]. 1971 Nov [cited 2017 Feb 10];21(11):1097–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/5166216

19. Martuscello RT, Vedam-Mai V, Mccarthy DJ, Schmoll ME, Jundi MA, Louviere CD, et al. Cancer Therapy: Preclinical A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma. Clin Cancer Res. 2015;22(10):2482–95.

20. James Lind Alliance Priority Setting Partnerships. Neuro-oncology Top 10 | James Lind Alliance [Internet]. Crown Copyright 2017. 2015 [cited 2017 Jan 10]. Available from: http://www.jla.nihr.ac.uk/priority-setting-partnerships/neuro-oncology/top-10-priorities/

21. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer [Internet]. 1993 Apr [cited 2017 Feb 13];67(4):773–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8471434

22. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20.

23. American Society for Parenteral and Enteral Nutrition. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. J Parenter Enter Nutr. 2002;26(Supplement 1).

24. Barak N, Wall-Alonso E, Sitrin M. Evaluation of stress factors and body weight adjustments currently used to estimate energy expenditure in hospitalized patients. J Parenter Enter Nutr [Internet]. 2002 Jul [cited 2017 Feb 13];26(4):231–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12090688

25. Department of Health. Dietary reference values for food energy and nutrients for the United Kingdom. H.M.S.O; 1991. 210 p.

26. Henry CJK. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr [Internet]. 2005 Oct [cited 2017 Feb 13];8(7A):1133–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16277825

27. Hyltander A, Drott C, Körner U, Sandström R, Lundholm K. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer Clin Oncol [Internet]. 1991 Jan [cited 2017 Feb 13];27(1):9–15. Available from: http://linkinghub.elsevier.com/retrieve/pii/027753799190050N

28. Knox LS, Crosby LO, Feurer ID, Buzby GP, Miller CL, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg [Internet]. 1983 Feb [cited 2017 Feb 13];197(2):152–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6824369

29. Todorovic V, Micklewright A. A Pocket Guide To Clinical Nutrition [Internet]. 4th ed. Birmingham: The Parenteral and Enteral Nutrition Group of the British Dietetic Association; 2011 [cited 2017 Feb 13]. Available from: http://www.peng.org.uk/publications-resources/pocket-guide.php

30. Barnard ND, Gloede L, Cohen J, Jenkins DJA, Turner-McGrievy G, Green AA, et al. A low-fat vegan diet elicits greater macronutrient changes, but is comparable in adherence and acceptability, compared with a more conventional diabetes diet among individuals with type 2 diabetes. J Am Diet Assoc [Internet]. 2009;109(2):263–72. Available from: http://dx.doi.org/10.1016/j.jada.2008.10.049

31. Jenkinson M. Walton Centre / Clatterbridge Centre for Oncology guidelines for high grade glioma management [Internet]. Merseyside and Cheshire Neuro-Oncology Clinical Network Group. Liverpool, UK; 2011 [cited 2017 Feb 13]. Available from: http://www.nwcscnsenate.nhs.uk/files/7114/1232/7814/High\_grade\_glioma\_guidelines\_November\_2013.pdf

32. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol [Internet]. 2010 Apr 10 [cited 2017 Feb 13];28(11):1963–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20231676

33. Meidenbauer JJ, Mukherjee P, Seyfried TN. The glucose ketone index calculator: a simple tool to monitor therapeutic e...: EBSCOhost. Nutr Metab [Internet]. 2015 [cited 2017 Jan 25];12(12):1–7. Available from: http://web.a.ebscohost.com.liverpool.idm.oclc.org/ehost/pdfviewer/pdfviewer?vid=15&sid=0fe16254-8549-4478-a717-36c8c7055bbf%40sessionmgr4008&hid=4212

34. Shanyinde M, Pickering RM, Weatherall M. Questions asked and answered in pilot and feasibility randomized controlled trials. BMC Med Res Methodol. 2011;11:117.

35. Bugge C, Williams B, Hagen S, Logan J, Glazener C, Pringle S, et al. A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse. Trials [Internet]. 2013;14(1):353. Available from: http://www.trialsjournal.com/content/14/1/353

36. Hooper. Justifying sample size for a feasibility study [Internet]. London; [cited 2017 May 22]. Available from: http://www.rds-london.nihr.ac.uk/RDSLondon/media/RDSContent/files/PDFs/Justifying-Sample-Size-for-a-Feasibility-Study\_1.pdf

37. Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med Res Methodol [Internet]. 2013 Dec 20 [cited 2017 May 22];13(1):104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23961782

38. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health [Internet]. 2008 Apr [cited 2017 May 22];31(2):180–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18183564

39. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol [Internet]. 2014 Mar 19 [cited 2016 Nov 15];117(1):125–31. Available from: http://link.springer.com/10.1007/s11060-014-1362-0

40. Strowd RE, Cervenka MC, Henry BJ, Kossoff EH, Hartman AL, Blakeley JO. Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. Neuro-Oncology Pract [Internet]. 2015 Sep [cited 2017 Jan 26];2(3):127–36. Available from: http://nop.oxfordjournals.org/lookup/doi/10.1093/nop/npv010

41. St. Joseph’s Hospital and Medical Center Phoenix. Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma [Internet]. Clinicaltrials.gov [Internet], Bethesda (MD): National Library of Medicine (US). 2017 [cited 2017 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show?term=ketogenic+diet+and+GBM&rank=2

42. Michigan State University. Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors (Ketones) [Internet]. Clinicaltrials.gov [Internet]. 2017 [cited 2017 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show?term=ketogenic+diet+and+GBM&rank=7

43. Kossoff EH, Al-Macki N, Cervenka MC, Kim HD, Liao J, Megaw K, et al. What are the minimum requirements for ketogenic diet services in resource-limited regions? Recommendations from the International League Against Epilepsy Task Force for Dietary Therapy. Epilepsia [Internet]. 2015 Sep [cited 2017 Feb 14];56(9):1337–42. Available from: http://doi.wiley.com/10.1111/epi.13039

44. Martin K, Jackson CF, Levy RG, Cooper PN. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2016;(2):Art. No.: CD001903.

45. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events v4.0 (CTCAE) [Internet]. 2009 [cited 2017 Feb 28]. Available from: https://www.eortc.be/services/doc/ctc/CTCAE\_4.03\_2010-06-14\_QuickReference\_5x7.pdf

46. National Institute for Health Research. Decision Tree for Adverse Event Reporting [Internet]. 2017 [cited 2017 Feb 28]. Available from: http://www.nihr.ac.uk/our-faculty/documents/Decision Tree for Adverse Event Reporting.pdf

1. Performance status (PS) 0 means normal activity; PS 1 means some symptoms but nearly fully ambulant; PS 2 means <50% daytime in bed; PS 3 means >50% daytime in bed; PS 4 is completely bed bound (21). [↑](#footnote-ref-1)